You have to login first.
AOR’s Mushroom Synergy is a synergistic blend of seven carefully chosen and well-studied mushrooms (Reishi, Maitake, Cordyceps, Lion’s Mane, Shitake, Turkey Tail, and Himematsutake) and two herbs (Astralagus and Holy Basil) that support immune health. Each has uniquely powerful properties; AOR has combined them to produce a complex, collaborative mechanism that helps protect the body from illness and infection. Mushroom Synergy helps increase energy and builds resistance when the body’s immune system is being weakened by stress. It helps the body to prevent, fight off, and treat bacterial and viral infections. It has been shown to be safe for use for those with acute or chronic immune-compromised conditions.
The immune system is a highly complex system composed of different types of white blood cells with various functions, including T-cells (which destroy infected cells), B-cells (which make antibodies), macrophages and neutrophils (which engulf invaders) and NK cells (which kill infected cells). AOR’s Mushroom Synergy combines seven potent mushroom species with two important immune-supporting herbs, ensuring that each step in the immune cascade is supported, including support against chronic
stress, which is a significant contributor to altered immune function. Mushroom Synergy contains naturally-occurring mushroom compounds that help to activate your pathogen-fighting white blood cells.
Source of mushroom polysaccharides with immune regulation and antioxidant properties. Used in herbal medicine to support healthy immune function. These mushroom species are combined with herbs to help increase energy*.
|AOR08155||90 Vegan Capsules|
|Serving Size: 2 Capsules||Amount||% Daily|
|Agaricus blazei (himematsutake) fruit body extract 30% Polyssacharides||33.33mg||†|
|Gandonerma lucidum (Reishi) fruit body extract 30% Polysaccharides||125mg||†|
|Grifola frondosa (Maitake) fruit body extract 30% Polysaccharides||133.33mg||†|
|Hericium erinaceus (Lion's mane) fruit body extract 30% Polysaccharides||200mg||†|
|Lentinus edodes (Shiitake) fruit body extract 30% polysaccharides||150mg||†|
|Ophiocordyceps sinensis (Cordyceps) fruit body extract 30% Polysaccharides||125mg||†|
|Trametes versicolor (Turkey Tail) fruit body extract 30% Polysaccharides||50mg||†|
|Astragalus (Astragalus membranaceus) root extract 20% Polysaccharides||166.67mg||†|
|Holy basil (Ocimum Sanctum) leaf extract 2% Ursolic acid||100mg||†|
AOR guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish or shellfish.
Take 2 capsules 1-3 times a day or directed by a health care practitioner. To avoid potential digestive upset, take with food/meal.
Do not use if pregnant. Consult a health care practitioner prior to use in breastfeeding; if you are taking blood thinning (anti-coagulant) or blood pressure (antihypertensive) medications. If you have an autoimmune disorder, diabetes, or a heart condition. Consult a healthcare practitioner if symptoms persist or worsen, and discontinue use if hypersensibility/allergic reactions occur.
These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Mushrooms are widely distributed around the world and are heavily consumed because of their nutritional value and medicinal properties. Polysaccharides (PSs) are an important component of mushrooms, a major factor in their bioactive properties, and have been intensively studied during the past two decades. Monosaccharide composition/combinations are important determinants of PS bioactivities. This review summarizes: (i) monosaccharide composition/combinations in various mushroom PSs, and their relationships with PS bioactivities; (ii) possible
biosynthetic pathways of mushroom PSs and effects of key enzymes on
monosaccharide composition; (iii) regulation strategies in PS biosynthesis, and
prospects for controllable biosynthesis of PSs with enhanced bioactivities.
Diabetes mellitus (DM) is the third most common non-infectious disease leading to early disability and high mortality. Moreover, the number of patients is growing every year. The main symptom of DM is hyperglycemia. Increased levels of blood glucose activate polyol, hexosamine, and protein kinase metabolic pathways cause the intensification of non-enzymatic glycosylation and nitration of macromolecules. This, in turn, leads to the development of oxidative and nitrative stresses and secondary complications, such as different kinds of micro- and macroangiopathies. Metabolic disorders caused by insulin deficiency in diabetes significantly impede the functioning of a homeostasis system, which change the physical, biochemical, morphological, and functional properties of blood cells. As a result, the oxygen-transport function of red blood cells (RBCs), rheological properties of the blood, and functions of immunocompetent cells as well as the process of apoptosis are primarily affected. Modern pharmacotherapy focuses on the search for new preparations that aim to decrease blood glucose levels. Undesirable side effects and adverse reactions caused by synthetic medicines led to the search and investigation of new preparations of natural origin. Medicinal mushrooms play an important role among such new preparations. They are a source of a large number of high- and low-molecular compounds with pronounced biological effects. Our investigations show pronounced hypoglycemic and anti-anemic action of submerged cultivated mycelium powder of medicinal mushrooms Agaricus brasiliensis (A. brasiliensis) and Ganoderma lucidum (G. lucidum) on streptozotocin-induced DM in rats. Also, we showed that mycelium powders have membrane protective properties as evidenced by the redistribution of RBC populations towards the growth of full functional cell numbers. Normalization of parameters of leukocyte formula and suppression of apoptosis of white blood cells in diabetic rats treated with A. brasiliensis and G. lucidum mycelia indicates pronounced positive effects of these strains of mushrooms. Thus, the use of medicinal mushrooms for treatment of DM and in prevention development of its secondary complications might be a new effective approach of this disease’s cure. This article is aimed at summarizing and analyzing the literature data and basic achievements concerning DM type 1 treatment using medicinal mushrooms and showing the results obtained in our research.
Hericium erinaceus (HE), a traditional edible mushroom, is known as a medicine food homology to ameliorate gastrointestinal diseases. To investigate whether HE is clinically effective in alleviating inflammatory bowel disease (IBD), HE extracts (polysaccharide, alcoholic extracts and whole extracts were prepared using solvent extraction methods) were administrated for 2 weeks in rats with IBD induced by trinitro-benzene-sulfonic acid (TNBS) enema (150 mg/kg). Significant clinical and histological changes in IBD rats were identified, including damage activity, common morphous and tissue damage index scores in colonic mucosa and myeloperoxidase (MPO) activity. The damage activity, common morphous and tissue damage index scores in colonic mucosa (P <0.05) were improved, MPO activities were decreased. Inflammatory factors were also differentially expressed in colonic mucosa in IBD rats, including serum cytokines, Foxp3 and interleukin (IL)-10 were increased while NF-κB p65 and tumor necrosis factor (TNF)-α were decreased (P <0.05), and T cells were activated (P <0.05), especially in the alcohol extracts-treated group. We also found that the structure of gut microbiota of the H. erinaceus extracts-treated groups changed significantly by compared with the model group. Further studies revealed that the polysaccharides in HE extracts may play a prebiotic role, whereas the alcoholic extracts show bactericidin-like and immunomodulatory effects. Taken together, we demonstrated that H. erinaceus extracts could promote the growth of beneficial gut bacteria and improve the host immunity in vivo IBD model, which shows clinical potential in relieving IBD by regulating gut microbiota and immune system.
The medicinal mushroom Agaricus blazei Murill from the Brazilian rain forest has been used in traditional medicine and as health food for the prevention of a range of diseases, including infection, allergy, and cancer. Other scientists and we have examined whether there is scientific evidence behind such postulations. Agaricus blazei M is rich in the immunomodulating polysaccharides, β-glucans, and has been shown to have antitumor, anti-infection, and antiallergic/-asthmatic properties in mouse models, in addition to anti-inflammatory effects in inflammatory bowel disease patients. These effects are mediated through the mushroom's stimulation of innate immune cells, such as monocytes, NK cells, and dendritic cells, and the amelioration of a skewed Th1/Th2 balance and inflammation.
There has been a significant increase in the use of mushrooms for therapeutic and medicinal purposes, in particular, use of the species Agaricus blazei Murrill, a basidiomycota of Brazilian origin. The objective of this study was to identify scientific evidence regarding the influence of A. blazei Murrill on the immune system. We undertook an integrative review of indexed publications published between 2000 and 2009, using the following question as a guideline: "What evidence can be found in the literature regarding the influence of A. blazei Murrill on the immune system?" Fourteen studies verified that there is in vitro and in vivo research demonstrating this mushroom's influence on the immune system. All research was characterized as evidence level 7 (preclinical study [animals/in vitro]). The research shows that A. blazei Murrill functions through bioactive compounds via mechanisms that are not yet entirely clear, although it has been shown that they promote action on the innate and adaptive immunological response, activation of the complement system, and synthesis of pro- and anti-inflammatory cytokines and even aid in diapedesis. Despite broad scientific evidence demonstrating relevant immunomodulatory properties of A. blazei Murrill, randomized clinical trials with human subjects are still needed in order for the mushroom to be put into clinical practice.
All rights Reserved. Copyright © by AOR 2019